The starting point for the jointly executed research project (Cluster 1) will be a comprehensive investigation into the genes (WP1) and proteins (WP2) that are expressed by DC stimulated by a variety of artificial and natural stimuli. New bioinformatic tools will also be developed, and databases will be constructed, to integrate, interpret and make available this knowledge and information across the Network and to others (WP3). It can be expected that new genes and proteins will be identified that can be targeted in the future for modulation of DC function in order to stimulate or suppress immune responses in a rational manner. For example, any genes of relevance that are identified will be cloned, inserted into relevant vectors (retrovirus / others), and tested in the biological systems described in subsequent Work packages (e.g. transgenic and knockout mice etc).

Particular attention will be paid to identifying genes and products that contribute to enhancement of DC function in experimental models of cancer and infectious disease (see Cluster 3). If, on the other hand, suppressive components are identified, monoclonal antibodies can be prepared and other strategies (e.g. siRNA) adopted to reverse their function, again for enhancement of immune responses. Any signatures reflective of enhancement or suppression of DC function may also be used as diagnostic markers before and after immunotherapy of cancer and HIV (see Cluster 4). Additionally, they may indicate novel mechanisms by which tumours and viruses can modulate DC function in vivo.